Nurix Therapeutics Inc Revenue Growth Rates (NRIX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Nurix Therapeutics Inc   (NASDAQ: NRIX)
 

NRIX's Revenue Growth by Quarter and Year

Nurix Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NRIX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter November -
3rd Quarter August -
2nd Quarter May 9.04
1st Quarter February 6.25
FY 15.29

NRIXs Annual Revenue
Nurix Therapeutics Inc 's Revenue in the fiscal year 2025 $ 83.98 millions
Nurix Therapeutics Inc 's Revenue in the fiscal year 2024 $ 54.55 millions
Nurix Therapeutics Inc 's Revenue in the fiscal year 2023 $ 76.99 millions
Nurix Therapeutics Inc 's Revenue in the fiscal year 2022 $ 38.63 millions
Nurix Therapeutics Inc 's Revenue in the fiscal year 2021 $ 29.75 millions




NRIX Revenue second quarter 2026 Y/Y Growth Comment
Nurix Therapeutics Inc reported drop in Revenue in the second quarter 2026 by -79.48% to $ 9.04 millions, from the same quarter in 2025.
The fall in the second quarter 2026 Nurix Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue jump of 44.08%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Revenue growth. While Nurix Therapeutics Inc ' s Revenue meltdown of -79.48% ranks overall at the positon no. 264 in the second quarter 2026.


NRIX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter November - 2.26 % -12.4 % 123.6 %
3rd Quarter August - -37.33 % -31.84 % 71.18 %
2nd Quarter May -79.48 % 264.43 % -60.59 % 168.42 %
1st Quarter February -66.12 % 11.21 % 30.73 % 31.91 %
FY   - 53.95 % -29.16 % -

Financial Statements
Nurix Therapeutics Inc 's second quarter 2026 Revenue $ 9.04 millions NRIX's Income Statement
Nurix Therapeutics Inc 's second quarter 2025 Revenue $ 44.06 millions Quarterly NRIX's Income Statement


NRIX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter November - 72.12 % 5.48 % -17.92 %
3rd Quarter August - -82.09 % 4.14 % -39.8 %
2nd Quarter May 44.69 % 138.81 % -27.12 % 141.77 %
1st Quarter February -53.98 % 38.93 % 9.43 % 87.17 %
FY (Year on Year)   - 53.95 % -29.16 % -


Back to NRIX Growth rate Comparisons >> Back to NRIX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #79
Overall #264

Revenue Y/Y Growth Statistics
High Average Low
219.79 % 44.08 % -58.4 %
(May 31 2022)   (May 31 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #79
Overall #264
Revenue Y/Y Growth Statistics
High Average Low
219.79 % 44.08 % -58.4 %
(May 31 2022)   (May 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Nurix Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
141.83 % 15.65 % -82.4 %
(May 31 2023)  


NRIX's II. Quarter Q/Q Revenue Comment
Nurix Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 44.69%, to $ 9.04 millions, from $6.25 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Nurix Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 290.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #74
Overall #290
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #74
Overall #290
Revenue Q/Q Growth Statistics
High Average Low
141.83 % 15.65 % -82.4 %
(May 31 2023)  


NRIX's II. Quarter Q/Q Revenue Comment
Nurix Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 44.69%, to $ 9.04 millions, from $6.25 millions in the first quarter.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Nurix Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 290.


Nurix Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(May 31 2026)		 12 Months Ending
(Feb 28 2026)		 12 Months Ending
(Nov 30 2025)		 12 Months Ending
(Aug 31 2025)		 12 Months Ending
(May 31 2025)
Cumulative Revenue 12 Months Ending $ 36.77 $ 71.78 $ 83.98 $ 83.69 $ 88.38
Y / Y Revenue Growth (TTM) -58.4 % 27.23 % 53.95 % 48.32 % 41.86 %
Year on Year Revenue Growth Overall Ranking # 358 # 79 # 113 # 48 # 1690
Seqeuential Revenue Change (TTM) -48.78 % -14.53 % 0.35 % -5.31 % 56.66 %
Seq. Revenue Growth (TTM) Overall Ranking # 264 # 48 # 94 # 47 # 2691


Cumulative Revenue growth Comment
For the 12 months ended May 31 2026 Nurix Therapeutics Inc reported a sharp drop in Revenue by -58.4% year on year, to $37 millions, compare to the 27.23% growth at Feb 28 2026.

In the Healthcare sector 97 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 79 to 358.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 44
Healthcare Sector # 98
Overall # 358

Revenue TTM Y/Y Growth Statistics
High Average Low
219.79 %
 44.08 %
-58.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 44
Sector # 79
S&P 500 # 264
Cumulative Revenue growth Comment
For the 12 months ended May 31 2026 Nurix Therapeutics Inc reported a sharp drop in Revenue by -58.4% year on year, to $37 millions, compare to the 27.23% growth at Feb 28 2026.

In the Healthcare sector 97 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 79 to 358.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 44
Healthcare Sector # 98
Overall # 358

Revenue TTM Y/Y Growth Statistics
High Average Low
219.79 %
44.08 %
-58.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 44
Sector # 79
S&P 500 # 264




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NRIX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue sharp drop for the quarter ending May 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending May 31 2026
Neogen Corporation-0.58%$ -0.581 millions
Cryo cell International Inc -1.93%$ -1.926 millions
Nurix Therapeutics Inc -79.47%$ -79.474 millions


About Nurix Therapeutics Inc Revenue Growth Rates (NRIX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Nurix Therapeutics Inc (CIK 1549595).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001549595-26-000040
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Nurix Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.